TY - JOUR
T1 - The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease
T2 - Potential contributions of environmental factors
AU - Pajarillo, Edward
AU - Rizor, Asha
AU - Lee, Jayden
AU - Aschner, Michael
AU - Lee, Eunsook
N1 - Funding Information:
The present study was supported in part by National Institutes of Health (NIH) R01 ES024756 (EL), R01 ES10563 (MA), 1R03 ES024849 (MA), R01 ES07331 (MA) and 1R21 ES025415 (MA).
Publisher Copyright:
© 2018
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD), and the most prevalent movement disorder. PD is characterized by dopaminergic neurodegeneration in the substantia nigra, but its etiology has yet to be established. Among several genetic variants contributing to PD pathogenesis, α-synuclein and leucine-rich repeat kinase (LRRK2) are widely associated with neuropathological phenotypes in familial and sporadic PD. α-Synuclein and LRRK2 found in Lewy bodies, a pathogenic hallmark of PD, are often posttranslationally modified. As posttranslational modifications (PTMs) are key processes in regulating the stability, localization, and function of proteins, PTMs have emerged as important modulators of α-synuclein and LRRK2 pathology. Aberrant PTMs altering phosphorylation, ubiquitination, nitration and truncation of these proteins promote PD pathogenesis, while other PTMs such as sumoylation may be protective. Although the causes of many aberrant PTMs are unknown, environmental risk factors may contribute to their aberrancy. Environmental toxicants such as rotenone and paraquat have been shown to interact with these proteins and promote their abnormal PTMs. Notably, manganese (Mn) exposure leads to a PD-like neurological disorder referred to as manganism—and induces pathogenic PTMs of α-synuclein and LRRK2. In this review, we highlight the role of PTMs of α-synuclein and LRRK2 in PD pathogenesis and discuss the impact of environmental risk factors on their aberrancy.
AB - Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD), and the most prevalent movement disorder. PD is characterized by dopaminergic neurodegeneration in the substantia nigra, but its etiology has yet to be established. Among several genetic variants contributing to PD pathogenesis, α-synuclein and leucine-rich repeat kinase (LRRK2) are widely associated with neuropathological phenotypes in familial and sporadic PD. α-Synuclein and LRRK2 found in Lewy bodies, a pathogenic hallmark of PD, are often posttranslationally modified. As posttranslational modifications (PTMs) are key processes in regulating the stability, localization, and function of proteins, PTMs have emerged as important modulators of α-synuclein and LRRK2 pathology. Aberrant PTMs altering phosphorylation, ubiquitination, nitration and truncation of these proteins promote PD pathogenesis, while other PTMs such as sumoylation may be protective. Although the causes of many aberrant PTMs are unknown, environmental risk factors may contribute to their aberrancy. Environmental toxicants such as rotenone and paraquat have been shown to interact with these proteins and promote their abnormal PTMs. Notably, manganese (Mn) exposure leads to a PD-like neurological disorder referred to as manganism—and induces pathogenic PTMs of α-synuclein and LRRK2. In this review, we highlight the role of PTMs of α-synuclein and LRRK2 in PD pathogenesis and discuss the impact of environmental risk factors on their aberrancy.
KW - LRRK2
KW - Manganese
KW - Parkinson's disease
KW - Posttranslational modifications
KW - α-Synuclein
UR - http://www.scopus.com/inward/record.url?scp=85057878442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057878442&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2018.11.017
DO - 10.1016/j.bbadis.2018.11.017
M3 - Article
C2 - 30481588
AN - SCOPUS:85057878442
SN - 0925-4439
VL - 1865
SP - 1992
EP - 2000
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 8
ER -